484 related articles for article (PubMed ID: 31494294)
1. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
Zhang T; Liu H; Li Y; Li C; Wan G; Chen B; Li C; Wang Y
Acta Biomater; 2019 Nov; 99():412-425. PubMed ID: 31494294
[TBL] [Abstract][Full Text] [Related]
2. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
Zhang S; Guo N; Wan G; Zhang T; Li C; Wang Y; Wang Y; Liu Y
J Nanobiotechnology; 2019 Oct; 17(1):109. PubMed ID: 31623608
[TBL] [Abstract][Full Text] [Related]
3. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
4. Rational design of multimodal therapeutic nanosystems for effective inhibition of tumor growth and metastasis.
Wang F; Huang Q; Wang Y; Zhang W; Lin R; Yu Y; Shen Y; Cui H; Guo S
Acta Biomater; 2018 Sep; 77():240-254. PubMed ID: 30012354
[TBL] [Abstract][Full Text] [Related]
5. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo.
Zheng G; Zheng M; Yang B; Fu H; Li Y
Biomed Pharmacother; 2019 Aug; 116():109006. PubMed ID: 31152925
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer.
Lee R; Choi YJ; Jeong MS; Park YI; Motoyama K; Kim MW; Kwon SH; Choi JH
Bioconjug Chem; 2020 Mar; 31(3):923-932. PubMed ID: 32027493
[TBL] [Abstract][Full Text] [Related]
7. Tailored design of multifunctional and programmable pH-responsive self-assembling polypeptides as drug delivery nanocarrier for cancer therapy.
Wang TW; Yeh CW; Kuan CH; Wang LW; Chen LH; Wu HC; Sun JS
Acta Biomater; 2017 Aug; 58():54-66. PubMed ID: 28606810
[TBL] [Abstract][Full Text] [Related]
8. PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy.
Yang H; Shen W; Liu W; Chen L; Zhang P; Xiao C; Chen X
Biomacromolecules; 2018 Nov; 19(11):4492-4503. PubMed ID: 30346147
[TBL] [Abstract][Full Text] [Related]
9. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment.
Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W
Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140
[TBL] [Abstract][Full Text] [Related]
10. Dual stimuli polysaccharide nanovesicles for conjugated and physically loaded doxorubicin delivery in breast cancer cells.
Pramod PS; Shah R; Jayakannan M
Nanoscale; 2015 Apr; 7(15):6636-52. PubMed ID: 25797322
[TBL] [Abstract][Full Text] [Related]
11. pH sensitive doxorubicin-loaded nanoparticle based on Radix pseudostellariae protein-polysaccharide conjugate and its improvement on HepG2 cellular uptake of doxorubicin.
Cai X; Yang Q; Weng Q; Wang S
Food Chem Toxicol; 2020 Feb; 136():111099. PubMed ID: 31883988
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
13. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
14. Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.
Sui J; Cui Y; Cai H; Bian S; Xu Z; Zhou L; Sun Y; Liang J; Fan Y; Zhang X
Nanoscale; 2017 Feb; 9(8):2755-2767. PubMed ID: 28155940
[TBL] [Abstract][Full Text] [Related]
15. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
16. Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells.
Sun N; Zhao C; Cheng R; Liu Z; Li X; Lu A; Tian Z; Yang Z
Mol Pharm; 2018 Aug; 15(8):3343-3355. PubMed ID: 29923726
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
18. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.
Mazzucchelli S; Bellini M; Fiandra L; Truffi M; Rizzuto MA; Sorrentino L; Longhi E; Nebuloni M; Prosperi D; Corsi F
Oncotarget; 2017 Jan; 8(5):8383-8396. PubMed ID: 28039473
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models.
Li M; Tang Z; Zhang D; Sun H; Liu H; Zhang Y; Zhang Y; Chen X
Biomaterials; 2015 May; 51():161-172. PubMed ID: 25771007
[TBL] [Abstract][Full Text] [Related]
20. Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis.
Yu RY; Xing L; Cui PF; Qiao JB; He YJ; Chang X; Zhou TJ; Jin QR; Jiang HL; Xiao Y
Biomater Sci; 2018 Jul; 6(8):2144-2155. PubMed ID: 29923556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]